Scholarlink

<p>Formation of anti-drug antibodies (ADA) and, in particular, neutralizing antibodies (NAb), is a major risk to the development of biotherapeutics. Cell-based assays, which can reflect the mechanistic interactions among the drug, target, and NAb, are often most suitable for the detection of NAb. We report the development and validation of cell-based platform assays for a class of incretin molecules. An affinity capture elution step was employed to improve drug tolerance of a cell-based cyclic adenosine monophosphate (cAMP) assay. Assay conditions and procedures, including acid elution, cell density, and TAG labeled cAMP (cAMP-TAG) incubation time and concentration, were thoroughly optimized. Delta percent (Δ%) Neutralization was used to reduce assay variability during validation and sample analysis. This platform method has been applied to several incretin molecules and has demonstrated desired sensitivity, drug tolerance, and robustness.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules

  • 期刊论文

  • 发表日期：

    2025年10月13日

查看全文
  • Nichole A. Reynolds,
  • Yan Q. Chen,
  • Richard E. Higgs,
  • Boris Calderon,
  • Jeff W. Cramer,
  • Nicoletta Bivi,
  • Michael E. Hodsdon,
  • Heather A. Bullock,
  • Travis E. Shockley,
  • Victoria L. Peek,
  • Justin K. Mack,
  • Deven Lemen,
  • Victoria Copeland,
  • Andrea Ferrante,
  • Robert J. Konrad,
  • Garrett Mullins,
  • Yi Wen

摘要

Formation of anti-drug antibodies (ADA) and, in particular, neutralizing antibodies (NAb), is a major risk to the development of biotherapeutics. Cell-based assays, which can reflect the mechanistic interactions among the drug, target, and NAb, are often most suitable for the detection of NAb. We report the development and validation of cell-based platform assays for a class of incretin molecules. An affinity capture elution step was employed to improve drug tolerance of a cell-based cyclic adenosine monophosphate (cAMP) assay. Assay conditions and procedures, including acid elution, cell density, and TAG labeled cAMP (cAMP-TAG) incubation time and concentration, were thoroughly optimized. Delta percent (Δ%) Neutralization was used to reduce assay variability during validation and sample analysis. This platform method has been applied to several incretin molecules and has demonstrated desired sensitivity, drug tolerance, and robustness.

Graphical Abstract